<DOC>
	<DOCNO>NCT00084825</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy docetaxel work different way stop tumor cell divide stop grow die . Imatinib mesylate may stop growth tumor cell block enzymes necessary growth . Giving docetaxel imatinib mesylate may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel imatinib mesylate work treat patient androgen-independent prostate cancer bone metastasis progress receive docetaxel placebo clinical trial MDA-ID-030008 .</brief_summary>
	<brief_title>Docetaxel Imatinib Mesylate Treating Patients With Androgen-Independent Prostate Cancer Bone Metastases That Progressed Docetaxel Placebo Group MDA-ID-030008</brief_title>
	<detailed_description>OBJECTIVES : Primary - Provide treatment docetaxel imatinib mesylate patient androgen-independent prostate cancer bone metastasis progress receive docetaxel placebo MDA-ID-030008 . Secondary - Determine response rate time progression patient crossover docetaxel placebo docetaxel imatinib mesylate . - Compare modulation platelet-derived growth factor receptor pathway docetaxel imatinib mesylate v docetaxel placebo patient . - Determine quality life patient treat crossover regimen . OUTLINE : This open-label , crossover , multicenter , extension study . Patients progress placebo docetaxel arm MDA-ID-030008 crossover receive docetaxel imatinib mesylate . Patients receive docetaxel IV 1 hour day 1 , 8 , 15 , 22 oral imatinib mesylate daily day 1-42 . Courses repeat every 42 day absence disease progression unacceptable toxicity . Quality life assess baseline , therapy course , completion therapy . Patients follow 30 day . PROJECTED ACCRUAL : A maximum 72 patient accrue study within 9 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma prostate Osseous metastasis Androgenindependent disease Previously randomize docetaxel placebo arm protocol MDAID030008 remove protocol due disease progression No 6 week since final treatment docetaxel placebo No uncontrolled brain metastasis spinal cord compression PATIENT CHARACTERISTICS : Age Any age Performance status Eastern Cooperative Oncology Group ( ECOG ) 03 Life expectancy Not specify Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2 time upper limit normal No chronic liver disease Renal Creatinine clearance ≥ 40 mL/min Cardiovascular No New York Heart Association class III IV congestive heart failure No unstable angina No uncontrolled severe hypertension No myocardial infarction within past 6 month Pulmonary No oxygendependent lung disease Other No prior doselimiting toxicity docetaxel require 2 dose reduction No severe hypersensitivity docetaxel No prior doselimiting toxicity docetaxel require 1 dose reduction AND experience recurrent grade 3 4 toxicity time progression MDAID030008 No uncontrolled diabetes mellitus No concurrent severe infection No overt psychosis , mental disability , incompetency would preclude give informed consent No history noncompliance HIV negative Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic therapy Chemotherapy See Disease Characteristics No concurrent chemotherapy Endocrine therapy No concurrent secondline hormonal therapy Radiotherapy At least 3 week since prior radiotherapy No recent strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium Surgery Recovered prior surgery Other No concurrent anticancer agents No concurrent investigational agent No concurrent therapeutic warfarin Concurrent minidose warfarin ( 1 mg/day ) central venous catheter prophylaxis allow No concurrent grapefruit grapefruit juice</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>